Allozyne
Allozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics.
Launch date
Employees
Market cap
-
Enterprise valuation
€5m (Public information from Sep 2014)
Seattle Washington (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$3.5m | Series A | ||
$30.0m | Series B | ||
N/A | $2.5m | Debt | |
N/A | $900k | Debt | |
$5.5m Valuation: $5.5m | Acquisition | ||
Total Funding | €30.5m |
Related Content
Recent News about Allozyne
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.